Kyverna Therapeutics, Inc. (KYTX), a biopharmaceutical company based in California, announced on Tuesday the appointment of Naji Gehchan as its Chief Medical and Development Officer. In this new role, Gehchan will manage the company's research, clinical development, and medical affairs divisions. With two decades of experience in both U.S. and international settings, Gehchan is well-versed in immunology and other therapeutic fields, bringing both pharmaceutical executive acumen and medical expertise to the company.
In the leadership transition, Dr. Dominic Borie, who has significantly contributed as Kyverna's founding CEO and more recently as President of Research and Development, will transition to the role of Strategic Advisor to the CEO and the Board. Dr. Borie's continued involvement will provide strategic guidance and leverage his extensive experience to benefit the company.
Dr. Naji Gehchan previously served at Eli Lilly, where he was pivotal as Head of Clinical Development for Imlunestrant, a breast cancer therapy, overseeing its progression from Phase 1 trials to global regulatory submissions. Over his 16-year tenure at Eli Lilly, he occupied senior positions such as Associate Vice President of Sales for U.S. Diabetes and Chief Marketing Officer for Lilly's operations in France, Belgium, and the Netherlands, where he spearheaded the launch of immunology medications.
On Tuesday, KYTX shares closed at $3.34, marking a slight increase of 0.3003%, and rose to $3.44, an additional 2.9940% increase, during after-market trading on the Nasdaq Global Select Market.
The material has been provided by InstaForex Company -
www.instaforex.com
